Canagliflozin Reduces Heart Failure Events Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results From the CANVAS Program
Circulation 2019 Mar 17;[EPub Ahead of Print], GA Figtree, K Rådholm, TD Barrett, V Perkovic, KW Mahaffey, D de Zeeuw, G Fulcher, DR Matthews, W Shaw, B NealFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.